Is Boston Scientific in line for a private equity takeover? | Wall Street Beat

February 24, 2012 by MassDevice staff

Is hedge fund giant David Tepper's new stake in Boston Scientific an indication that it's ripe for a private equity buyout?; also, OTC lists Titan Medical; Burrill & Co. opens in Taiwan; MGT Capital plans reverse split to stay on NYSE; plus a Deals Roundup, a Funding Roundup and analysts' ups and downs.

MassDevice.com Wall Street Beat

Billionaire hedge fund manager David Tepper, of Appaloosa Management, bought 7.8 million shares of Boston Scientific stock during the 4th quarter, according to regulatory filings, for a stake with a market value of $41.6 million as of Dec. 31.

That could be a sign that rumors of a private equity takeover have some substance, according to TheStreet.com. Appaloosa's stake in BSX accounts for about 6% of its entire, $765 million portfolio, according to the website. With share prices holding steady at the low price of about $6, Tepper's interest could signal that the rumors are right.

"Given Tepper's involvement, we think [a PE takeover] could be the case – making Boston Scientific (NYSE:BSX) a great speculative play. It is priced low enough to be an OK investment in the short term, but if the company is taken over, the returns could be magical," according to The Street.

Sign up to get our free newsletters delivered straight to your inbox

BSX shares broke the $6 mark today, closing up 5.9% at $6.25 for the day.

Comments